NEW YORK, June 5, 2026, 08:03 (EDT)
- CollPlant ended Thursday at $0.3949, down 1.25% for the session, with no new trading before Friday’s open. Nasdaq does not have a full-market holiday listed on its 2026 calendar until Juneteenth on June 19.
- CollPlant Biotechnologies Ltd. has until Sept. 21 to get back in line with Nasdaq’s $1 minimum bid rule. Shares must close at or above $1 for at least 10 straight business days.
- CollPlant’s Q1 update put revenue at $73,000 with a net loss of $3.1 million and $4.3 million in cash as of March 31.
CollPlant Biotechnologies Ltd. (CLGN) was quoted at $0.3949 before the Friday open on the Nasdaq, staying under 40 cents as investors looked at the company’s strategic review, limited cash, and an upcoming exchange deadline. Shares slipped 1.25% to close at $0.3949 on Thursday.
This is an issue now as the stock still trades under the Nasdaq’s $1 minimum bid. The company needs the closing bid—meaning the last quoted bid at the market close—to hit at least $1 for 10 straight business days by Sept. 21, or it won’t fix the problem.
Market sentiment stayed weak early. Nasdaq 100 futures dropped 0.88% at 6:41 a.m. ET, with chip stocks under pressure and traders focused on the upcoming U.S. payrolls data. Barclays strategist Emmanuel Cau called the AI and semiconductor trade “more shaky.” Reuters
CollPlant’s most recent company update is still the May 29 first-quarter report. GAAP revenue dropped sharply, down to $73,000 from $2.1 million the prior year, with the company saying it didn’t get a repeat of last year’s $2 million milestone payment, which was booked in Q1 2025. Net loss increased to $3.1 million, or 23 cents a share.
CollPlant Biotechnologies Ltd. reported $4.3 million in cash and cash equivalents as of March 31. The company used $3.0 million in operating cash for the quarter and got $1.7 million in net proceeds through a February registered direct offering. Management said cost cutting during the quarter included reducing headcount by roughly 50%.
CollPlant’s stock focus is shifting from sales to the hunt for a deal or a partner. CEO Yehiel Tal said in the first quarter CollPlant started talks with “several leading strategic players” in medical aesthetics. CFO Eran Rotem said the company is looking at “strategic alternatives” that could include acquisitions, strategic transactions or business combinations. CollPlant Biotechnologies Ltd.
CollPlant’s main focus is rhCollagen, a recombinant human collagen produced with its plant platform, so it’s not animal-derived. The company is working on a dermal-filler platform for aesthetics, still in preclinical stages and not yet in human trials. This uses rhCollagen mixed with hyaluronic acid and other ingredients.
Competition is front and center. Allergan Industrie SAS, part of AbbVie, ended its CollPlant deal in April. The two had been developing a dermal and soft-tissue filler with CollPlant’s tech. CollPlant said it is now looking for new aesthetics partners.
But the risks are clear. Partner talks might not lead to a deal, there’s no set timeline for the strategic review, and CollPlant could need new funding with tough terms if cash runs low. The Nasdaq notice also puts the company at risk of a reverse share split or even delisting if it can’t solve the bid-price issue.
CollPlant shares could see movement this week as investors look for news on a possible partner, updates on the strategic review, or signs buyers are stepping in below $1. CollPlant has said there will be no more updates on the review unless it is legally required or the company decides an update is necessary.
